🦊/Companies

Mogrify Limited

4 known investors

Find your way into Mogrify Limited

729 people in our graph share verified history with the Mogrify Limited team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Julian Gough · together at University of Cambridge (overlapped)
×3knows the team · via University of Bristol
×5knows the team · via University of Cambridge
×3knows the team · via Stanford University School of Medicine

Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another. It targets diseases with high unmet clinical need, initially in otology, ophthalmology, and diabetes.

Founders & leadership

JGJulian Gough
Julian GoughinCo-founderJulian Gough is co-founder of Mogrify, a biotechnology company developing cellular reprogramming therapies. He previously held academic positions with publications in computational methods for molecular and cell biology, and founded other companies including OutSee, focused on genomics analysis for drug discovery.
OROwen Rackham
Owen RackhaminCo-founderOwen Rackham is co-founder of Mogrify Limited, a biotechnology company developing in vivo cellular reprogramming therapies. His research background spans computational biology and machine learning applied to large-scale biological datasets, with focus on understanding cellular state transitions and identifying therapeutic interventions grounded in experimental validation.
JP
Jose PoloinCo-founder
DMDarrin M. Disley
Darrin M. Disleyin𝕏CEODarrin Disley is CEO of Mogrify Limited and has founded, grown, or invested in over 40 life science and technology companies. He previously co-founded gene editing company Horizon Discovery Group Plc, which he led from seed funding to a £113M IPO on AIM, and has held executive roles at Cardiogeni Plc and Roquefort Therapeutics Plc.

Board

JO
Jane OsbournChair

Investors · 4

Also in the syndicate · 1

Trend Investment Group

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Companies House · registry record

View on Companies House ↗
Registered name
MOGRIFY LIMITED
Company number
10002103
Status
Active
Company type
Private limited company
Incorporated
12 Feb 2016
Registered office
25 Cambridge Science Park, Milton Road, Cambridge, CB4 0FW
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Previous names
CELL MOGRIFY LIMITED (20162019)
Accounts
last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement
last made up to 21 Mar 2026 · next due 4 Apr 2027

Current officers · 4

  • Joe Caddell director, appointed 19 Feb 2026
  • Joe Alan Foster director, appointed 13 Dec 2022
  • Julian Gough director, appointed 12 Feb 2016
  • Joanna Charlotte Antonia Green director, appointed 21 Jan 2021

Source: Companies House public register · retrieved 8 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Frequently asked questions

What does Mogrify Limited do?
Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another. It targets diseases with high unmet clinical need, initially in otology, ophthalmology, and diabetes.
Who founded Mogrify Limited?
Mogrify Limited was founded by Julian Gough, Owen Rackham, Jose Polo.
Who are Mogrify Limited's investors?
Mogrify Limited's investors include Ahren Innovation Capital, Astellas Venture Management LLC, Parkwalk Advisors.